Skip to Navigation | Skip to Main Content | Skip to Site Map

MyFloridaHouse.gov | Mobile Site

Senate Tracker: Sign Up | Login

The Florida Senate

HB 7097 — Direct Support Organization of the Prescription Drug Monitoring Program

by Health Quality Subcommittee and Rep. Fine (SB 7006 by Health Policy Committee and Senator Benacquisto)

This summary is provided for information only and does not represent the opinion of any Senator, Senate Officer, or Senate Office.

Prepared by: Health Policy Committee (HP)

HB 7097 extends the scheduled repeal date of the direct support organization (DSO) of the Florida Prescription Drug Monitoring Program (PDMP) to October 1, 2027. At that time, if not reenacted by the Legislature, the DSO will be repealed.

A DSO is a private entity created to assist or support a governmental entity in carrying out its duties. In 2014, the Legislature conducted a review of the existing relationships between DSOs and their governmental partners. One of the results of that review was legislation that established operational requirements and standards for DSOs with an automatic review and repeal date for each organization.

The Florida PDMP Foundation, Inc., (Foundation) was created as a DSO in 2009 for the prescription drug monitoring program. The PDMP uses an electronic database to track the prescribing and dispensing of certain controlled substances to patients. The mission of the Foundation is twofold: to fundraise for the benefit of the PDMP, in order to reduce prescription drug abuse and diversion, and to educate licensed health care providers and law enforcement providers on how to utilize the database in the management of controlled substances in patient care and active law enforcement investigations.

If approved by the Governor, these provisions take effect July 1, 2017.

Vote: Senate 37-0; House 117-0